ea0084op-07-34 | Oral Session 7: Thyroid Cancer Basic | ETA2022
Pita Jaime M
, Coulonval Katia
, Costante Giuseppe
, Myriam Decaussin
, Emmanuelle Leteurtre
, Cavaco Branca
, A Copland John
, Durante Cosimo
, Maenhaut Carine
, Dumont Jacques
, Roger Pierre
, Raspe Eric
Introduction and objectives: The cyclin-dependent kinases CDK4 and CDK6 are key regulators of the cell cycle entry, by phosphorylating the onco-suppressor retinoblastoma protein (pRb). CDK4/6 inhibitors (CDK4i) are already established as standard first-line treatment against advanced Estrogen Receptor-positive breast tumors, and have emerged as novel drugs to treat various pRb-proficient chemotherapy-resistant cancers. Presence of activating T172-phosphorylation of CDK4 in bre...